Activation of NFκB signaling in the skin was identified as the primary cause of the chronic proliferative dermatitis phenotype in Sharpincpdm mutant mice and inhibition of NFκB activation by bortezormib can alleviate the skin phenotype suggesting a treatment for some forms of hypereosinophilic syndrome in humans. Here, NFKB1 is linked to hypereosinophilic syndrome.